340 related articles for article (PubMed ID: 25787923)
1. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
Chiorean EG; Hurwitz HI; Cohen RB; Schwartz JD; Dalal RP; Fox FE; Gao L; Sweeney CJ
Ann Oncol; 2015 Jun; 26(6):1230-1237. PubMed ID: 25787923
[TBL] [Abstract][Full Text] [Related]
2. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Spratlin JL; Cohen RB; Eadens M; Gore L; Camidge DR; Diab S; Leong S; O'Bryant C; Chow LQ; Serkova NJ; Meropol NJ; Lewis NL; Chiorean EG; Fox F; Youssoufian H; Rowinsky EK; Eckhardt SG
J Clin Oncol; 2010 Feb; 28(5):780-7. PubMed ID: 20048182
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors.
Nokihara H; Yamamoto N; Yamada Y; Honda K; Asahina H; Tamura Y; Hozak RR; Gao L; Suzukawa K; Enatsu S; Tamura T
Jpn J Clin Oncol; 2017 Apr; 47(4):298-305. PubMed ID: 28158463
[TBL] [Abstract][Full Text] [Related]
5. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.
Zhu AX; Finn RS; Mulcahy M; Gurtler J; Sun W; Schwartz JD; Dalal RP; Joshi A; Hozak RR; Xu Y; Ancukiewicz M; Jain RK; Nugent FW; Duda DG; Stuart K
Clin Cancer Res; 2013 Dec; 19(23):6614-23. PubMed ID: 24088738
[TBL] [Abstract][Full Text] [Related]
6. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
[TBL] [Abstract][Full Text] [Related]
7. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
[TBL] [Abstract][Full Text] [Related]
8. Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.
LoRusso PM; Krishnamurthi S; Youssoufian H; Hall N; Fox F; Dontabhaktuni A; Grebennik D; Remick S
Invest New Drugs; 2014 Apr; 32(2):303-11. PubMed ID: 23903897
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.
Lee SJ; Lee SY; Lee WS; Yoo JS; Sun JM; Lee J; Park SH; Park JO; Ahn MJ; Lim HY; Kang WK; Park YS
Invest New Drugs; 2017 Dec; 35(6):782-790. PubMed ID: 28391576
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
Vahdat LT; Layman R; Yardley DA; Gradishar W; Salkeni MA; Joy AA; Garcia AA; Ward P; Khatcheressian J; Sparano J; Rodriguez G; Tang S; Gao L; Dalal RP; Kauh J; Miller K
Oncologist; 2017 Mar; 22(3):245-254. PubMed ID: 28220020
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors.
Niwakawa M; Yamaguchi R; Onozawa Y; Yasui H; Taku K; Naito T; Akinaga S; Boku N; Yamamoto N
Cancer Sci; 2013 Aug; 104(8):1039-44. PubMed ID: 23679664
[TBL] [Abstract][Full Text] [Related]
13. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Azad NS; Posadas EM; Kwitkowski VE; Steinberg SM; Jain L; Annunziata CM; Minasian L; Sarosy G; Kotz HL; Premkumar A; Cao L; McNally D; Chow C; Chen HX; Wright JJ; Figg WD; Kohn EC
J Clin Oncol; 2008 Aug; 26(22):3709-14. PubMed ID: 18669456
[TBL] [Abstract][Full Text] [Related]
14. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
[TBL] [Abstract][Full Text] [Related]
15. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
[TBL] [Abstract][Full Text] [Related]
16. Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors.
Cao J; Ji D; Chen Z; Shen W; Wang J; Li B; Chi H; Long A; Gao L; Li J
Oncologist; 2017 Jun; 22(6):638-e56. PubMed ID: 28465370
[TBL] [Abstract][Full Text] [Related]
17. A phase ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas.
Ueda S; Satoh T; Gotoh M; Gao L; Doi T
Oncologist; 2015 May; 20(5):493-4. PubMed ID: 25888272
[TBL] [Abstract][Full Text] [Related]
18. A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.
Harding JJ; Zhu AX; Bauer TM; Choueiri TK; Drilon A; Voss MH; Fuchs CS; Abou-Alfa GK; Wijayawardana SR; Wang XA; Moser BA; Uruñuela A; Wacheck V; Bendell JC
Clin Cancer Res; 2019 Sep; 25(17):5202-5211. PubMed ID: 31142504
[TBL] [Abstract][Full Text] [Related]
19. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
Patnaik A; LoRusso PM; Messersmith WA; Papadopoulos KP; Gore L; Beeram M; Ramakrishnan V; Kim AH; Beyer JC; Mason Shih L; Darbonne WC; Xin Y; Yu R; Xiang H; Brachmann RK; Weekes CD
Cancer Chemother Pharmacol; 2014 May; 73(5):951-60. PubMed ID: 24633809
[TBL] [Abstract][Full Text] [Related]
20. Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study.
Masuda N; Iwata H; Aogi K; Xu Y; Ibrahim A; Gao L; Dalal R; Yoshikawa R; Sasaki Y
Jpn J Clin Oncol; 2016 Dec; 46(12):1088-1094. PubMed ID: 27608646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
